Simultaneous determination of albendazole sulfoxide and praziquantel from PLGA nanoparticles and validation of new HPLC method

Abstract

A simple, rapid and reproducible HPLC method has been developed and validated for the quantification of albendazole sulfoxide (ALBSOX) and praziquantel (PRZ), which can coexist in various dosage forms. Chromatographic separation was performed in gradient mode using a mobile phase consisting of an InertSustain® C18 column (150 × 4.6 mm, 5 µm) and acetonitrile: water (v/v) at a flow rate of 1.0 mL/min. The active substance peaks were well separated and detected by a DAD detector at 217 nm. The HPLC method was linear for ALBSOX and PRZ in the concentration range of 0.1-50 µg/mL. Limit of detection (LOD) was found to be 0.01 µg/mL for ALBSOX and 0.009 µg/mL for PRZ. The limit of quantification (LOQ) was found to be 0.03 µg/mL for ALBSOX and 0.027 µg/mL for PRZ. The developed HPLC method was validated based on ICH guidelines for specificity, linearity, system suitability, precision and accuracy. The method was applied for simultaneous quantification and characterization studies of ALBSOX and PRA in PLGA nanoparticles.

Keywords

• Albendazole sulfoxide
• HPLC method
• nanoparticle
• praziquantel
• validation

References

1. [1] Torabi N, Dobakhti F, Faghihzadeh S, Haniloo A. In vitro and in vivo effects of chitosan-praziquantel and chitosan-albendazole nanoparticles on Echinococcus granulosus Metacestodes. Parasitol Res. 2018;117(7):2015–23. [CrossRef]
2. [2] Torgerson P, Motarjemi Y. Helminth-Cestode: Echinococcus granulosus and Echinococcus mutilocularis. In: Motarjemi Y, (Ed). Encyclopedia of Food Safety. Waltham, 2014, pp. 63–69.
3. [3] Mihmanli M, Idiz UO, Kaya C, Demir U, Bostanci O, Omeroglu S, Bozkurt E. Current status of diagnosis and treatment of hepatic echinococcosis. World J Hepatol. 2016;8(28):1169. [CrossRef]
4. [4] Skuhala T, Trkulja V, Runje M, Balen-Topić M, Vukelić D, Desnica B. Combined albendazole-praziquantel treatment in recurrent brain echinococcosis: case report. Iran J Parasitol. 2019;14(3):492–96.
5. [5] Alvela-Suárez L, Velasco-Tirado V, Belhassen-Garcia M, Novo-Veleiro I, Pardo-Lledías J, Romero-Alegría A, et al. Safety of the combined use of praziquantel and albendazole in the treatment of human hydatid disease. Am J Trop Med Hyg. 2014;90(5):819–22. [CrossRef]
6. [6] Lima RM, Ferreira MAD, de Jesus Ponte Carvalho TM, Fernandes BJD, Takayanagui OM, Garcia HH, et al. Albendazole–praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity. Br J Clin Pharmacol. 2011;71(4):528–35. [CrossRef]
7. [7] Mohamed A, Yasawy M, Al Karawi M. Combined albendazole and praziquantel versus albendazole alone in the treatment of hydatid disease. Hepatogastroenterology. 1998;45(23):1690–4.
8. [8] Cobo F, Yarnoz C, Sesma B, Fraile P, Aizcorbe M, Trujillo R, et al. Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatidosis caused by Echinococcus granulosus. Trop Med Int Health. 1998;3(6):462–6. [CrossRef]

9. [9] Yetim İ, Erzurumlu K. Current approaches in treatment of hydatid cysts of liver. J Clin Anal Med. 2013;4(1):64–71.
10. [10] Dehkordi AB, Sanei B, Yousefi M, Sharafi SM, Safarnezhad F, Jafari R, et al. Albendazole and treatment of hydatid cyst: review of the literature. Infect Disord Drug Targets. 2019;19(2):101–4. [CrossRef]
11. [11] Chai J-Y. Praziquantel treatment in trematode and cestode infections: an update. Infect Chemother. 2013;45(1):32–43. [CrossRef]
12. [12] Dil EA, Asfaram A, Javadian H. A new approach for microextraction of trace albendazole sulfoxide drug from human plasma, urine, and water using molecularly imprinted polymer nanoparticles combined with HPLC. J Chromatogr. 2020;1158:122249. [CrossRef]
13. [13] Anacleto SdS, de Oliveira HL, da Silva ATM, do Nascimento TA, Borges MMC, Silva RCdS, et al. Assessment of hybrid molecularly imprinted polymer for enantioselective determination of albendazole sulfoxide. J Chromatogr Sci. 2019;57(7):671–8. [CrossRef]
14. [14] Kitzman D, Cheng K-J, Fleckenstein L. HPLC assay for albendazole and metabolites in human plasma for clinical pharmacokinetic studies. J Pharm Biomed Anal. 2002;30(3):801–13. [CrossRef]
15. [15] Wu Z, Medlicott NJ, Razzak M, Tucker IG. Development and optimization of a rapid HPLC method for analysis of ricobendazole and albendazole sulfone in sheep plasma. J Pharm Biomed Anal. 2005;39(1–2):225–32. [CrossRef]
16. [16] Belaz KRA, Denadai M, Almeida AP, Lima RT, Vasconcelos MH, Pinto MM, et al. Enantiomeric resolution of albendazole sulfoxide by semipreparative HPLC and in vitro study of growth inhibitory effects on human cancer cell lines. J Pharm Biomed Anal. 2012;66:100–8. [CrossRef]
17. [17] Hanpitakpong W, Banmairuroi V, Kamanikom B, Choemung A, Na-Bangchang K. A high-performance liquid chromatographic method for determination of praziquantel in plasma. J Pharm Biomed Anal. 2004;36(4):871–6. [CrossRef]
18. [18] Tatar E, Gökhan A, Küçükgüzel İ. Development and validation of a RP-HPLC method for quality control of oxantel pamoate, pyrantel pamoate and praziquantel in tablets. Marmara Pharm J. 2015;19(1):27–35.
19. [19] Li J, Wang Y, Fenwick A, Clayton TA, Lau YY, Legido-Quigley C, et al. HPLC and NMR-based analysis of commercial praziquantel tablets. J Pharm Biomed Anal. 2007;45(2):263–7. [CrossRef]
20. [20] Shah SR, Dey S, Pradhan P, Jain H, Upadhyay UM. Method development and validation for simultaneous estimation of albendazole and praziquantel. J Taibah Univ Sci. 2014;8(1):54–63. [CrossRef]
21. [21] Shah S, Dey S, Kant K, Behera PC, Ghosh M. Simultaneous determination of albendazole and praziquantel in rat plasma by HPLC-UV. 21st Int Electron Conf Synth Org Chem. 2017. [CrossRef]
22. [22] Vignaduzzo SE, Operto MA, Castellano PM. Development and validation of a dissolution test method for albendazole and praziquantel in combined dosage. J Mex Chem Soc. 2015;26:729–35. [CrossRef]
23. [23] Gandla K, Lalitha R, Bommakanti S, Suthakaran R, Pallavi K. Development and validation of RP-HPLC method for simultaneous estimation of albendazole and praziquantel in tablets. Asian J Pharm Anal. 2015;5(3):115–8. [CrossRef]
24. [24] Bonato PS, De Oliveira ARM, De Santana FJM, Fernandes BJD, Lanchote VL, Gonzalez AE, et al. Simultaneous determination of albendazole metabolites, praziquantel and its metabolite by LC-MS. J Pharm Biomed Anal. 2007;44(2):558–63. [CrossRef]
25. [25] Kumar L, Reddy MS, Managuli RS, Pai G. Full factorial design for HPLC method development for valsartan in nanoparticles. Saudi Pharm J. 2015;23(5):549–55. [CrossRef]
26. [26] ICH Guideline. Validation of analytical procedures: text and methodology Q2 (R1). 2005;1(20):05.
27. [27] Ahmadnia S, Moazeni M, Mohammadi-Samani S, Oryan A. In vivo evaluation of albendazole sulfoxide and its solid lipid nanoparticles against hydatid cyst. Exp Parasitol. 2013;135(2):314–9. [CrossRef]
28. [28] Darvishi MM, Moazeni M, Alizadeh M, Abedi M, Tamaddon A-M. Efficacy of ABZ-SO-loaded chitosan-PLGA nanoparticles in cystic echinococcosis. Parasitol Res. 2020;119(12):4233–41. [CrossRef]
29. [29] Naseri M, Akbarzadeh A, Spotin A, Akbari NAR, Mahami-Oskouei M, Ahmadpour E. Scolicidal activity of ABZ-SO-loaded PLGA-PEG nanoparticles. Parasitol Res. 2016;115(12):4595–603. [CrossRef]
30. [30] Gonzalez MA, Rigo R, González Vidal NL. Orphan formulations in pediatric schistosomiasis: praziquantel nanoparticle powders. AAPS PharmSciTech. 2019;20(8):1–12. [CrossRef]
31. [31] Andrade LN, Oliveira DM, Chaud MV, Alves TF, Nery M, da Silva CF, et al. Praziquantel–solid lipid nanoparticles by SC-CO₂: characterization and cytotoxicity. Molecules. 2019;24(21):3881. [CrossRef]
32. [32] Emami J, Ghassami N, Ahmadi F. New HPLC method for lamotrigine and related compounds in tablets. J Pharm Biomed Anal. 2006;40(4):999–1005. [CrossRef]
33. [33] Gedawy A, Al-Salami H, Dass CR. New HPLC method for simultaneous determination of metformin and gliclazide. J Food Drug Anal. 2019;27(1):315–22. [CrossRef]
34. [34] Sagirli O, Onal A, Toker S, Şensoy D. Simultaneous HPLC analysis of olmesartan and hydrochlorothiazide. Chromatographia. 2007;66(3):213–8. [CrossRef]
35. [35] Rao BM, Sangaraju S, Srinivasu M, Madhavan P, Devi ML, et al. Stability-indicating HPLC method for rizatriptan benzoate. J Pharm Biomed Anal. 2006;41(4):1146–51. [CrossRef]
36. [36] Dewani A, Dabhade S, Bakal R, Gadewar C, Chandewar A, Patra S. RP-HPLC method for determination of multiple drugs in tablets. Arab J Chem. 2015;8(4):591–8. [CrossRef]
37. [37] British Pharmacopoeia. Her Majesty’s Stationery Office, 1998. p. 1416.
38. [38] Beasley CA, Shaw J, Zhao Z, Reed RA. Stability-indicating HPLC method for lisinopril and parabens. J Pharm Biomed Anal. 2005;37(3):559–67. [CrossRef]